William D. Tap, MD - The Case for Challenging Conventional Care in Tenosynovial Giant Cell Tumor: Insights on Integrating Targeted Therapy Into Multimodal Management

Go online to PeerView.com/SUZ860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. In this PeerView virtual activity, following the 2020 connective tissue oncology annual meeting, a panel of leading clinicians provides insights on important medical evidence supporting targeted agents in tenosynovial giant cell tumor (TGCT), and modern, practical recommendations for overcoming patient care challenges in the management of TGCT. The panel will also provide a multidisciplinary perspective on real-world clinical scenarios and discuss how novel targeted therapeutics have enhanced a long-standing treatment landscape. Upon completion of this activity, participants should be better able to: Describe the clinical signs and symptoms of localized and diffuse tenosynovial giant cell tumor (TGCT), including recurrent disease, Explain the biologic rationale and clinical evidence for the use of targeted options in the management of TGCT, Integrate targeted options into the management of TGCT patients who are unlikely to benefit from surgical interventions, Recommend multidisciplinary approaches for the management of TGCT, including localized and diffuse disease.